William Blair analyst Andrew Brackmann has reiterated their bullish stance on MDXH stock, giving a Buy rating yesterday.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Andrew Brackmann has given his Buy rating due to a combination of factors that suggest a positive outlook for MDxHealth. Despite a slight miss in third-quarter revenue expectations, the company maintained profitability and reduced cash usage significantly. The management’s decision to delay the launch of germline testing and focus on the integration of ExoDx is seen as a strategic move that supports long-term growth prospects.
The company’s revenue guidance remains strong, and the integration of ExoDx is expected to contribute positively, offsetting any short-term challenges. The stock is currently trading at a valuation that appears to undervalue its growth potential and commercial infrastructure. Brackmann remains confident in MDxHealth’s trajectory and believes the company is well-positioned for future growth opportunities, reinforcing his Buy rating.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $7.00 price target.